Evolent Health Inc (EVH) Short Interest Update

Evolent Health Inc (NYSE:EVH) was the recipient of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 13,347,473 shares, a decline of 24.3% from the October 31st total of 17,633,685 shares. Currently, 20.7% of the company’s shares are sold short. Based on an average trading volume of 3,770,134 shares, the short-interest ratio is presently 3.5 days.

Shares of Evolent Health (EVH) opened at $12.85 on Monday. Evolent Health has a 52-week low of $10.30 and a 52-week high of $27.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 3.34.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. The business had revenue of $107.90 million for the quarter, compared to analysts’ expectations of $104.49 million. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The firm’s revenue was up 79.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.26) EPS. research analysts forecast that Evolent Health will post -0.57 EPS for the current year.

EVH has been the subject of several research analyst reports. BidaskClub lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Cowen reissued an “outperform” rating and issued a $29.00 price target (down previously from $33.00) on shares of Evolent Health in a report on Friday, October 6th. SunTrust Banks reissued a “buy” rating and issued a $30.00 price target on shares of Evolent Health in a report on Friday, November 3rd. Jefferies Group reissued a “buy” rating and issued a $28.00 price target on shares of Evolent Health in a report on Wednesday, September 6th. Finally, J P Morgan Chase & Co reissued a “buy” rating on shares of Evolent Health in a report on Friday, August 18th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $28.00.

Institutional investors and hedge funds have recently bought and sold shares of the stock. ETF Managers Group LLC bought a new stake in Evolent Health in the 2nd quarter valued at $102,000. BNP Paribas Arbitrage SA lifted its position in Evolent Health by 815.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after acquiring an additional 4,232 shares in the last quarter. SG Americas Securities LLC bought a new stake in Evolent Health in the 3rd quarter valued at $156,000. IPG Investment Advisors LLC bought a new stake in Evolent Health during the 3rd quarter worth about $195,000. Finally, First Mercantile Trust Co. bought a new stake in Evolent Health during the 2nd quarter worth about $198,000. 95.38% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Evolent Health Inc (EVH) Short Interest Update” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/04/evolent-health-inc-evh-short-interest-update.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

What are top analysts saying about Evolent Health Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Evolent Health Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit